Literature DB >> 7811035

Effect of macrophage colony-stimulating factor on anticryptococcal activity of bronchoalveolar macrophages: synergy with fluconazole for killing.

E Brummer1, F Nassar, D A Stevens.   

Abstract

The anticryptococcal activity of murine bronchoalveolar macrophages (BAM) and their synergy with fluconazole (FCZ) was studied. BAM cultured with tissue culture medium for 48 to 72 h were fungicidal (24 to 39%) in a 3-h killing assay. However, net killing of Cryptococcus neoformans did not continue when culture time was extended to 24 h, although BAM were fungistatic (88 to 98%). Treatment with macrophage colony-stimulating factor (M-CSF; 5,000 U/ml, 48 h) did not significantly increase BAM killing of a low challenge dose in 3-h assays compared with control BAM. However, M-CSF-treated BAM were significantly more fungistatic against higher challenge doses in the 3-h assays. FCZ was not fungicidal at 5 micrograms/ml but was highly fungistatic (98 and 99% at 24 and 48 h, respectively). M-CSF-treated BAM acted synergistically with FCZ (2.5 micrograms/ml) for significantly greater killing than control BAM, 55% versus 20% and 96% versus 45% at 24 h and 48 h, respectively. Killing by M-CSF BAM and FCZ (5.0 micrograms/ml) was significantly (P < 0.01) greater than that by control BAM and FCZ at 48 h. These findings indicate an important collaborative role for BAM and FCZ in killing C. neoformans, and this is enhanced by M-CSF.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7811035      PMCID: PMC284700          DOI: 10.1128/AAC.38.9.2158

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro.

Authors:  R D Diamond; R K Root; J E Bennett
Journal:  J Infect Dis       Date:  1972-04       Impact factor: 5.226

2.  Macrophage colony-stimulating factor induction of enhanced macrophage anticryptococcal activity: synergy with fluconazole for killing.

Authors:  E Brummer; D A Stevens
Journal:  J Infect Dis       Date:  1994-07       Impact factor: 5.226

3.  Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion.

Authors:  L H Hanson; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

4.  Enhanced oxidative burst in immunologically activated but not elicited polymorphonuclear leukocytes correlates with fungicidal activity.

Authors:  E Brummer; A M Sugar; D A Stevens
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

5.  Regulation of colony-stimulating activity production. Interactions of fibroblasts, mononuclear phagocytes, and lactoferrin.

Authors:  G C Bagby; E McCall; D L Layman
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

6.  Murine pulmonary macrophages: evaluation of lung lavage fluids, miniaturized monolayers, and candidacidal activity.

Authors:  A M Sugar; E Brummer; D A Stevens
Journal:  Am Rev Respir Dis       Date:  1983-01

7.  Both granulocyte-macrophage CSF and macrophage CSF control the proliferation and survival of the same subset of alveolar macrophages.

Authors:  H S Lin; B L Lokeshwar; S Hsu
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

8.  Detection of endogenous macrophage colony-stimulating factor (M-CSF) in human blood.

Authors:  P J Shadle; J I Allen; M D Geier; K Koths
Journal:  Exp Hematol       Date:  1989-02       Impact factor: 3.084

9.  Macrophage colony-stimulating factor enhances monocyte and macrophage antibody-dependent cell-mediated cytotoxicity.

Authors:  R A Mufson; J Aghajanian; G Wong; C Woodhouse; A C Morgan
Journal:  Cell Immunol       Date:  1989-03       Impact factor: 4.868

10.  Paradoxical role of capsule in murine bronchoalveolar macrophage-mediated killing of Cryptococcus neoformans.

Authors:  S M Levitz; D J DiBenedetto
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

View more
  4 in total

1.  Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice.

Authors:  K V Clemons; J E Lutz; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection.

Authors:  T Kuhara; K Uchida; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 3.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

4.  Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity.

Authors:  F Nassar; E Brummer; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.